Still waiting to hear about final approval for my trial, and hope to get started soon. I did have blood work done this week, and want to share a couple interesting values. I have never had very high CA 19-9 or CEA levels going all the way back to when I was first diagnosed with PDAC in March 2023.
CEA was highest at 9.9 in April 2023 and low was 2.0 last July. It mostly sat between 4 and 6 during my year plus of chemo.
CA 19-9 was highest at 21 in Jan 2024 and sat mostly in the 9-15 range. So never even close to "out of range".
My blood tests this weeks showed CA 19-9 is still low at 6. My CEA has crept up and was one of the early signs along with CT scans that my cancer was returning. 4.8 in Fed, 7.7 a month ago, and 10.7 this week. I know that's all still relatively low for many cases.
I guess the conclusion is this is evidence that the cancer itself has changed since it has now spread in my abdomen, and there is nothing seen on scans in my pancreas? Should it even be called PC any more even though that is the origin? I guess it's all semantics but I am trying to get a handle on how/if this cancer going forward is different than when I had a known tumor on my pancreas (that has been removed).
Since your CA 19-9 is not necessarily predictive, I might suggest asking your doctors to do the Signatera blood test by Natera. New so that when my scans are clear. It lets us know something is brewing.
My pancreas tumor has been gone since 2022 but we still relate emerging tumors to metastases since the little cowboys can hide for quite awhile before they decide to post up somewhere.
Among other things I am now looking for a blood test for mutations. A recent tissue biopsy was unsuccessful but I am interested to know if I have now experienced further mutations after all this. My known or KRAS G12D and TP53 but my doctor says it is likely there could be a new mutation.